 | This is a user sandbox of Immcarle51. You can use it for testing or practicing edits. This is not the sandbox where you should draft your assigned article for a dashboard.wikiedu.org course. To find the right sandbox for your assignment, visit your Dashboard course page and follow the Sandbox Draft link for your assigned article in the My Articles section. |
MHC class II **added into the article!**
Having MHC class II molecules present proper peptides that are bound stably is essential for overall immune function. The peptide presented regulates how T cells respond to an infection. Stable peptide binding is essential to prevent detachment and degradation of a peptide, which could occur without secure attachment to the MHC molecule. This would prevent T cell recognition of the antigen, T cell recruitment, and a proper immune response.[1]
CLIP: **added into the article!**
Function
editThe nascent MHC class II protein in the rough ER binds a segment of the invariant chain (Ii; a trimer) in order to shape the peptide binding groove and prevent formation of a closed conformation.
The invariant chain also facilitates MHC class II's export from the ER in a vesicle. The signal for endosomal targeting resides in the cytoplasmic tail of the invariant chain. This fuses with a late endosome containing the endocytosed antigen proteins (from the exogenous pathway). Binding to Ii ensures that no antigen peptides from the endogenous pathway meant for MHC class I molecules accidentally bind to the groove of class II molecules. [1] The Ii is then cleaved by cathepsin S (cathepsin L in cortical thymic epithelial cells), leaving only a small fragment called CLIP remaining bound to the groove of MHC class II molecules. The rest of the Ii is degraded.[1] CLIP blocks peptide binding until HLA-DM interacts with MHC II, releasing CLIP and allowing other peptides to bind. In some cases, CLIP dissociates without any further molecular interactions, but in other cases the binding to the MHC is more stable.[2] The stable MHC class-II with antigen is then presented on the cell surface. Without CLIP, MHC class II aggregates, disassemble, and/or denature in the endosomes, and proper antigen presentation is impaired.[3]
HLA-DM
HLA-DM
editHLA-DM (human leukocyte antigen DM) is an intracellular protein involved in the immune system's response to an antigen.[4] It does this by assisting in peptide loading of major histocompatibility complex (MHC) class II membrane-bound proteins.[5] HLA-DM is encoded by the genes HLA-DMA and HLA-DMB.
HLA-DM is a molecular chaperone[3] that works in lysosomes and endosomes in cells of the immune system. It works in antigen presenting cells (APCs) like macrophages, dendritic cells, and B cells [6] by interacting with MHC class II molecules.[7] HLA-DM protects the MHC class II molecules from breaking down and regulates which proteins or peptides bind to them as well. Once bound, a peptide can act as an antigen to initiate an immune response. Thus, HLA-DM is necessary for the immune system to respond effectively. Impairment in HLA-DM function can result in immunodeficiency and autoimmune diseases.
Function
edit
MHC class II + peptide interactions
editHLA-DM is an integral protein in the mechanism regulating which antigens are presented extracellularly on APCs. It binds to the peptide-binding groove of MHC class II molecules. This can affect how well your immune system responds to foreign invaders.
HLA-DM is required to release CLIP from MHC class II molecules, to chaperone empty MHC molecules against denaturation, and to control proper loading and release of peptides at the peptide-binding groove.[2] It also interacts heavily with chaperone protein HLA-DO. All of this ensures proper antigen presentation by an APC, to activate other immune cells. This is critical to rid your body of harmful infections. For example, proper antigen presentation benefits T cell activation, and memory T cell survival and generation. Without it, T cells leaving their site of production and entering the circulatory vessels of the body will not be activated against a danger.[8] The immune system will not be able to kill dangerous or infected cells, and will not react quickly against a second infection.
MHC class II molecule stabilization - chaperonal function
editThe low pH of lysosomes could cause denaturation or proteolysis of MHC class II molecules. HLA-DM binding to MHC stabilizes and protects from degradation, by covering hydrophobic surfaces.[3] Antigen degradation could also ensue, resulting in an inability to bind to the peptide-binding groove. Thus, HLA-DM is needed to protect proteins against the lysosomal environment.[3]
CLIP release
editIn order to ensure that no false peptides bind to an MHC class II molecule, the peptide-binding groove is occupied by a protein called CLIP. Once a proper peptide is encountered, HLA-DM catalyzes the exchange of CLIP for an antigen peptide.[1] Often, this peptide is retrieved directly from the B cell receptor which internalized it. Through expulsion of CLIP at the proper time, HLA-DM ensures that the correct antigen can bind to MHC molecules and prevent either from degrading.
Antigen loading and release
editApart from CLIP-antigen exchange, HLA-DM also facilitates antigen-antigen exchange. It releases weakly bound peptides from the groove to load peptides with higher-affinity binding. This process occurs in endosomes once they have left the ER containing MHC and HLA-DM that have fused with antigen-containing lysosomes.[1] Kinetic analysis studies have shown that HLA-DM loading occurs quickly and in many endosomes. Along the membrane of an endosome at the optimal acidity (pH=5.0), HLA-DM loads 3 to 12 peptides onto different MHC molecules per minute.[3]
Recently, HLA-DM has also been found to assist in catalysis of peptide exchange not only in endosomes traveling from the ER, but also on cell membranes and in early endosomes. Much of this pathway is still being researched, but it is known that HLA-DM can load exogenous peptides onto MHC class II molecules when they are being expressed on cell surfaces. Loading can also occur in early endosomes that are quickly recycled. In both of these areas, loading occurs slower due to an altered pH environment.
Release
To release peptides from the MHC groove, HLA-DM binds to the N terminus of the groove, altering its conformation and breaking hydrogen bonds[4] such that the peptide that was interacting with the MHC groove can no longer bind and is ejected.[9]
Loading
Quick loading of peptides, facilitated by a stable MHC-DM complex, decreases the chances of those peptides being broken down by the proteolytic environment in the endosome.[2] HLA-DM dissociates from the MHC once a stable enough peptide has bound.[3] Thus, only antigens that can ‘out compete’ others by binding strongly enough to the groove end up on the surface of the antigen presenting cells in MHC class II molecules.[1]
Interaction with HLA-DO
editHLA-DM also binds to HLA-DO, another non-classical MHC molecule. HLA-DO starts binding to DM in early endosomes, but is expressed less in late endosomes/lysosomes.[10] The binding between HLA-DM and HLA-DO is less strong at low pH, but overall much stronger than HLA-DM binding to MHC molecules.[8]
Before encountering an antigen, DO acts as a chaperone of DM to stabilize it against denaturation and direct it into lysosomes. It binds in the same location to HLA-DM as MHC class II molecules bind, thereby preventing HLA-DM from binding to MHC class II molecules. This inhibits peptide exchange catalysis and keeps CLIP in the MHC groove[1] until antigen-containing lysosome fuses with DM/DO/MHC containing lysosomes, prompting the degradation of HLA-DO molecules in MIICs.[8]
Expression and Location
editFirst translated in the endoplasmic reticulum, it is then transported to endosomal MHC class II compartments (MIICs). MIICs then join with endosomes containing MHC class II molecules bound to an invariant chain. Here, the HLA-DM begins editing the MHC peptide binding.[4]
HLA-DM is also expressed on the surface of B cells and dendritic cells,[6] as well as in secreted exosomes.[11]
During B cell development, HLA-DM is first expressed in early stages in the bone marrow. Expression then remains high throughout development and a B cell’s life, until the B cell differentiates into a plasma cell and HLA-DM expression then decreases.[8]
Proper antigen presentation benefits T cell activation, and memory T cell survival and generation. If there are no antigens presented in MHC molecules, T cells leaving the thymus will not be activated.[8]
Role in Disease and Medicine
editImmunodeficiency
editIn individuals lacking functional HLA-DM molecules, improper antigen presentation occurs, resulting in unwanted immune responses or lack of a response when danger is present.[9] This has been shown experimentally through mouse knockout models.[3] There will be an increase of CLIP, instead of peptide, presentation on APC surfaces. This can result in autoimmunity, if a T cell receptors recognize CLIP as a harmful antigen. There could also be no protein presentation at all, resulting in a lack of immune response.[9]
Infections and Disease
editType 1 diabetes is correlated with DM activation, which is hypothesized to be due to DM positively modulating the expression of disease-causing peptides in the MHC groove and thus presented to responding T cells.[10] Experiments using the mouse model of type 1 diabetes which blocked DM or reduced its activity by overexpressing DO found a decrease in diabetes.[10]
HLA-DM is implicated in viral infections like Herpes Simplex Virus Type 1. This virus causes uneven distribution of HLA-DM in endosomes, prevents peptide catalysis, and prevents presentation of MHC class II molecules on the cell surface.[4]
HLA-DM is also implicated in celiac disease, multiple sclerosis, other autoimmune diseases, and leukemia.[6][12][13]
Genetics
editThe gene for HLA-DM is on human chromosome 6 in the MHC class II region.[4] It is nonpolymorphic.[9]
Structure & Binding
editRecent developments in crystallography have resulted in advanced knowledge on HLA-DM structure, and how it binds to its substrates (HLA-DO and MHC class II molecules).
HLA-DM Structure
editThe structure and sequence of HLA-DM proteins is very similar to other MHC class II molecules,[2] all of which consist of a heterodimer composed of an alpha and beta chain. However, HLA-DM differs in that it is nonclassical (meaning it lacks a transport signal N-terminus), and does not have the capability to bind peptides. This is due to lack of a deep peptide binding groove - instead, it contains a shallow, negatively charged indent with two disulfide bonds.[3]
On its beta chain cytoplasmic tail, a tyrosine based motif YTPL regulates trafficking to specific endosomal compartments called MHC class II compartments (MIICs) from the ER.[4]
HLA-DM and MHC class II binding
editHLA-DM catalyzes peptide exchange through binding at the beta chain of MHC class II molecules,[1] which alters the conformation of the MHC and its peptide-binding groove. HLA-DM conformation stays constant.[14] When a peptide is bound to the P1 locus in the peptide binding groove, it is stably bound. This also hinders HLA-DM binding to the MHC, preventing destabilization of the peptide-MHC interaction.[10] Peptides also bind to the C-terminal site of the binding groove, but in this case the binding is a weak association, leaving the N-terminal of the groove open. HLA-DM can then bind to the N-terminal and allowing for peptide exchange.[10]
HLA-DM and HLA-DO binding
editHLA-DO binds to the same regions of HLA-DM as MHC class II molecules do, such that it blocks the ability of HLA-DM to bind with MHC.[10] Thus, you can never have a complex containing HLA-DM, HLA-DO, and MHC class II molecules.
----
Sources, Articles
editgood overview: HLA-DM – an endosomal and lysosomal chaperone for the immune system (1999) https://www.sciencedirect.com/science/article/pii/S096800049901364X?via%3Dihub
HLA-DM Website by Davidson College (2006) http://www.bio.davidson.edu/Courses/immunology/Students/spring2006/McCracken/HLA-DM.html
HLA-DM and HLA-DO, key regulators of MHC-II processing and presentation (2014) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3944065/
Mechanisms of peptide repertoire selection by HLA-DM (2013) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3796002/
The impact of the non-classical MHC proteins HLA-DM and HLA-DO on loading of MHC class II molecules (1999) https://www.ncbi.nlm.nih.gov/pubmed/10631952
Immunopathology of childhood celiac disease—Key role of intestinal epithelial cells (2017) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5608296/
HLA-DM acts as a molecular chaperone and rescues empty HLA-DR molecules at lysosomal pH (1997) https://www.ncbi.nlm.nih.gov/pubmed/9075930
Peptidomic analysis of type 1 diabetes associated HLA-DQ molecules and the impact of HLA-DM on peptide repertoire editing (2016) http://onlinelibrary.wiley.com/doi/10.1002/eji.201646656/full
Achieving stability through editing and chaperoning: regulation of MHC class II peptide binding and expression http://search.ebscohost.com/login.aspx?direct=true&db=keh&AN=18333090&site=ehost-live&scope=site
Interaction of HLA-DR with an Acidic Face of HLA-DM Disrupts Sequence-Dependent Interactions with Peptides (2003) https://www.sciencedirect.com/science/article/pii/S1074761303002000?via%3Dihub
Functional HLA-DM on the surface of B cells and immature dendritic cells (2000) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC305665/
Multiple sclerosis
- ^ a b c d e f g h A., Owen, Judith (2013). Kuby immunology. Punt, Jenni., Stranford, Sharon A., Jones, Patricia P., Kuby, Janis. (7th ed ed.). New York: W.H. Freeman. ISBN 9781464119910. OCLC 820117219.
{{cite book}}:|edition=has extra text (help)CS1 maint: multiple names: authors list (link) - ^ a b c d Schulze, Monika-Sarah ED; Wucherpfennig, Kai W. "The mechanism of HLA-DM induced peptide exchange in the MHC class II antigen presentation pathway". Current Opinion in Immunology. 24 (1): 105–111. doi:10.1016/j.coi.2011.11.004.
- ^ a b c d e f g h Vogt, Anne B; Kropshofer, Harald. "HLA-DM – an endosomal and lysosomal chaperone for the immune system". Trends in Biochemical Sciences. 24 (4): 150–154. doi:10.1016/s0968-0004(99)01364-x.
- ^ a b c d e f "Russ McCracken: HLA-DM". www.bio.davidson.edu. Retrieved 2018-03-05.
- ^ Busch, Robert; Rinderknecht, Cornelia H.; Roh, Sujin; Lee, Andrew W.; Harding, James J.; Burster, Timo; Hornell, Tara M. C.; Mellins, Elizabeth D. (2005-10-01). "Achieving stability through editing and chaperoning: regulation of MHC class II peptide binding and expression". Immunological Reviews. 207 (1): 242–260. doi:10.1111/j.0105-2896.2005.00306.x. ISSN 1600-065X.
- ^ a b c Arndt, Sven O.; Vogt, Anne B.; Markovic‐Plese, Silva; Martin, Roland; Moldenhauer, Gerhard; Wölpl, Alois; Sun, Yuansheng; Schadendorf, Dirk; Hämmerling, Günter J. (2000-03-15). "Functional HLA‐DM on the surface of B cells and immature dendritic cells". The EMBO Journal. 19 (6): 1241–1251. doi:10.1093/emboj/19.6.1241. ISSN 0261-4189. PMID 10716924.
- ^ Pashine, Achal; Busch, Robert; Belmares, Michael P.; Munning, Jason N.; Doebele, Robert C.; Buckingham, Megan; Nolan, Gary P.; Mellins, Elizabeth D. "Interaction of HLA-DR with an Acidic Face of HLA-DM Disrupts Sequence-Dependent Interactions with Peptides". Immunity. 19 (2): 183–192. doi:10.1016/s1074-7613(03)00200-0.
- ^ a b c d e Adler, Lital N.; Jiang, Wei; Bhamidipati, Kartik; Millican, Matthew; Macaubas, Claudia; Hung, Shu-chen; Mellins, Elizabeth D. (2017). "The Other Function: Class II-Restricted Antigen Presentation by B Cells". Frontiers in Immunology. 8. doi:10.3389/fimmu.2017.00319. ISSN 1664-3224.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - ^ a b c d Yin, Liusong; Maben, Zachary J.; Becerra, Aniuska; Stern, Lawrence J. (2015-07-15). "Evaluating the Role of HLA-DM in MHC Class II–Peptide Association Reactions". The Journal of Immunology. 195 (2): 706–716. doi:10.4049/jimmunol.1403190. ISSN 0022-1767. PMID 26062997.
- ^ a b c d e f Mellins, Elizabeth D; Stern, Lawrence J. "HLA-DM and HLA-DO, key regulators of MHC-II processing and presentation". Current Opinion in Immunology. 26: 115–122. doi:10.1016/j.coi.2013.11.005.
- ^ Xiu, Fangming; Côté, Marie-Hélène; Bourgeois-Daigneault, Marie-Claude; Brunet, Alexandre; Gauvreau, Marie-Élaine; Shaw, Andrew; Thibodeau, Jacques (2011-08-15). "Cutting Edge: HLA-DO Impairs the Incorporation of HLA-DM into Exosomes". The Journal of Immunology. 187 (4): 1547–1551. doi:10.4049/jimmunol.1100199. ISSN 0022-1767. PMID 21768396.
- ^ Wang, Jie; Song, Di; Liu, Yanzi; Lu, Guangjian; Yang, Shuai; Liu, Lu; Gao, Zhitao; Ma, Lingling; Guo, Zhixiang (2017-10-31). "HLA-DMB restricts human T-cell leukemia virus type-1 (HTLV-1) protein expression via regulation of ATG7 acetylation". Scientific Reports. 7 (1). doi:10.1038/s41598-017-14882-z. ISSN 2045-2322.
- ^ Pietz, Grzegorz; De, Rituparna; Hedberg, Maria; Sjöberg, Veronika; Sandström, Olof; Hernell, Olle; Hammarström, Sten; Hammarström, Marie-Louise (2017-09-21). "Immunopathology of childhood celiac disease—Key role of intestinal epithelial cells". PLOS ONE. 12 (9): e0185025. doi:10.1371/journal.pone.0185025. ISSN 1932-6203.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - ^ Yin, Liusong; Trenh, Peter; Guce, Abigail; Wieczorek, Marek; Lange, Sascha; Sticht, Jana; Jiang, Wei; Bylsma, Marissa; Mellins, Elizabeth D. (2014-08-22). "Susceptibility to HLA-DM Protein Is Determined by a Dynamic Conformation of Major Histocompatibility Complex Class II Molecule Bound with Peptide". Journal of Biological Chemistry. 289 (34): 23449–23464. doi:10.1074/jbc.m114.585539. ISSN 0021-9258. PMID 25002586.
{{cite journal}}: CS1 maint: unflagged free DOI (link)